Market Place
Sourcing Support
Voting Rights & Shares Capital of the Company
13 Nov 2024 //
GLOBENEWSWIRE
Nanobiotix Q3 2024 Update & Progress on Nanotherapeutics Platform
12 Nov 2024 //
GLOBENEWSWIRE
NANOBIOTIX to Attend Investor Conferences in November
31 Oct 2024 //
GLOBENEWSWIRE
Voting Rights and Shares Capital of the Company
11 Oct 2024 //
GLOBENEWSWIRE
Nanobiotix Reports Half Year 2024 Financial Results
18 Sep 2024 //
GLOBENEWSWIRE
NANOBIOTIX Adds Two Key Members To Supervisory Board
04 Sep 2024 //
GLOBENEWSWIRE
Nanobiotix to Present at H.C. Wainwright 26th Annual Global Conference
03 Sep 2024 //
GLOBENEWSWIRE
Voting Rights and Shares Capital of the Company
08 Aug 2024 //
GLOBENEWSWIRE
Voting Rights and Shares Capital of the Company
09 Jul 2024 //
GLOBENEWSWIRE
NANOBIOTIX To Host Virtual KOL Event On NBTXR3 In Cancer
12 Jun 2024 //
GLOBENEWSWIRE
Voting Rights and Shares Capital of the Company
11 Jun 2024 //
GLOBENEWSWIRE
NBTXR3 Activates Tumor Response In Anti-PD-1 Resistant/Naïve R/M HNSCC
02 Jun 2024 //
GLOBENEWSWIRE
NANOBIOTIX: New Phase 1 Immuno-Oncology Data, Investor Call At ASCO 2024
28 May 2024 //
GLOBENEWSWIRE
NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
23 May 2024 //
GLOBENEWSWIRE
NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update
22 May 2024 //
GLOBENEWSWIRE
Dyne`s $305M offering; Nanobiotix delays Ph2 readout
22 May 2024 //
ENDPTS
Nanobiotix Highlights NBTXR3 Pipeline Progress, Growth Pathway
21 May 2024 //
GLOBENEWSWIRE
Voting Rights and Shares Capital of the Company
16 May 2024 //
GLOBENEWSWIRE
NANOBIOTIX To Announce Q1 Operational, Financial Update On May 22
15 May 2024 //
GLOBENEWSWIRE
NANOBIOTIX Announces FDA Phase 2 Lung Cancer Study Protocol Acceptance
14 May 2024 //
GLOBENEWSWIRE
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
24 Apr 2024 //
GLOBENEWSWIRE
NANOBIOTIX Reports Q4 2023 and FY 2023 Results on April 24, 2024
17 Apr 2024 //
GLOBENEWSWIRE
Nanobiotix Announces Completion of Ph 1 Dose Escalation & NBTXR3 Ph 2 Dose
02 Apr 2024 //
GLOBENEWSWIRE
Nanobiotix to Present at Upcoming Investor Conferences in March
06 Mar 2024 //
GLOBENEWSWIRE
Voting Rights and Shares Capital of the Company
13 Feb 2024 //
GLOBENEWSWIRE
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
31 Jan 2024 //
GLOBENEWSWIRE
Nanobiotix Announces Achievement of $20M Development Milestone Payment
29 Jan 2024 //
GLOBENEWSWIRE
Voting Rights and Shares Capital of the Company
11 Jan 2024 //
GLOBENEWSWIRE
Nanobiotix Partner LianBio Assigns Its Development Rights for NBTXR3
26 Dec 2023 //
GLOBENEWSWIRE
Voting Rights and Shares Capital of the Company
13 Dec 2023 //
GLOBENEWSWIRE
NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update
09 Nov 2023 //
GLOBENEWSWIRE
Voting Rights and Shares Capital of the Company
08 Nov 2023 //
GLOBENEWSWIRE
NANOBIOTIX Announces Closing of Global Offering
07 Nov 2023 //
GLOBENEWSWIRE
NANOBIOTIX Announces Availability of a Prospectus with Capital Increases
06 Nov 2023 //
GLOBENEWSWIRE
NANOBIOTIX Announces Pricing of a Capital Increase
02 Nov 2023 //
GLOBENEWSWIRE
NANOBIOTIX Announces Launch of Global Concurrent Private Placement
01 Nov 2023 //
GLOBENEWSWIRE
NANOBIOTIX Announces Updated Results From Phase 1 Pancreatic Cancer Trial
23 Oct 2023 //
GLOBENEWSWIRE
Voting Rights and Shares Capital of the Company
11 Oct 2023 //
GLOBENEWSWIRE
Nanobiotix Announces the Presentation of Analysis From Phase 1 Evaluating NBTXR3
04 Oct 2023 //
GLOBENEWSWIRE
NANOBIOTIX Announces Presentation of Data From Phase 1 Study Evaluating NBTXR3
28 Sep 2023 //
GLOBENEWSWIRE
NANOBIOTIX Provides Financial Results for the First Half of 2023
26 Sep 2023 //
GLOBENEWSWIRE
Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023
19 Sep 2023 //
GLOBENEWSWIRE
NANOBIOTIX Appoints Leader Dr. Louis Kayitalire as Chief Medical Officer
05 Sep 2023 //
GLOBENEWSWIRE
NANOBIOTIX to Present at the H.C. Wainwright 25th Annual Conference
31 Aug 2023 //
GLOBENEWSWIRE
NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement
15 Aug 2023 //
GLOBENEWSWIRE
NANOBIOTIX to Host General Meeting of Shareholders on September 1st, 2023
04 Aug 2023 //
GLOBENEWSWIRE
Voting Rights and Shares Capital of the Company
20 Jul 2023 //
GLOBENEWSWIRE
NANOBIOTIX Announces First Patient Injected in Phase 1/2 Study Evaluating NBTXR3
19 Jul 2023 //
GLOBENEWSWIRE
LianBio Partner NANOBIOTIX Enters into Agreement with Janssen for NBTXR3
18 Jul 2023 //
GLOBENEWSWIRE
J&J Extends Lifeline to Nanobiotix in Potential $1.8B Licensing Deal
11 Jul 2023 //
BIOSPACE
NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update
17 May 2023 //
GLOBENEWSWIRE
NANOBIOTIX Entering Final Contract Negotiations Following Agreement
04 May 2023 //
GLOBENEWSWIRE
Nanobiotix Provides Business Update and Reports Full Year 2022 Financial Results
24 Apr 2023 //
GLOBENEWSWIRE
NANOBIOTIX to Provide Operational Update and Report Full Year 2022FYR
17 Apr 2023 //
GLOBENEWSWIRE
Voting Rights and Shares Capital of the Company
11 Apr 2023 //
GLOBENEWSWIRE
Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call
27 Mar 2023 //
GLOBENEWSWIRE
Nanobiotix to Report Full Year 2022 Financial Results on March 28, 2023
14 Mar 2023 //
GLOBENEWSWIRE
Voting Rights and Shares Capital of the Company
14 Feb 2023 //
GLOBENEWSWIRE
Voting Rights and Shares Capital of the Company
11 Jan 2023 //
GLOBENEWSWIRE
NANOBIOTIX Announces First Patient Randomized in US in Global Ph3 Pivotal Tria
27 Dec 2022 //
GLOBENEWSWIRE
